Publication of early but impressive data for GlaxoSmithKline PLC’s combination of dabrafenib and trametinib for metastatic melanoma could justify off-label use if FDA approves the drugs as single agents, a development that could damage Roche/Genentech Inc.’s BRAF inhibitor Zelboraf.
Dabrafenib, a BRAF inhibitor, and trametinib, a first-in-class MEK inhibitor, are both pending approval as monotherapies with FDA, following presentation of positive single-agent data for both at the American Society...